Th22细胞及IL-22因子在原发性肝细胞肝癌发生发展中的表达及意义

doi:10.3969/j.issn.2095-9400.2019.01.004

Abstract
Figure/Table
References (0)
Related Citation (10)

Download: PDF (1418 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the expression and significance of Th22 cells and IL-22 in the development and progression of primary hepatocellular carcinoma. Methods: A total of 42 hospitalized patients with chronic hepatitis B cirrhosis (cirrhosis group), 38 hospitalized patients with hepatocellular carcinoma (hepatocellular carcinoma group), 30 healthy volunteers (healthy group) and 21 cases of chronic hepatitis B (CHB group) were randomly selected from the Third Affiliated Hospital of Wenzhou Medical University from January 2015 to December 2016. The differences in AST, ALT, TBIL and ALB values were analyzed. Blood was collected intravenously into 2 heparin anticoagulant tubes, one for testing IL-22 expression level and the other for determination of Th22 cell levels using flow cytometry. The statistics of Th22 and IL-22 levels were analyzed. Results: The AST, ALT, TBIL and ALB values in patients with cirrhosis and hepatocellular carcinoma were significantly higher than those in the CHB group and healthy group (P<0.01). The AST, ALT, TBIL and ALB values of patients in the hepatocellular carcinoma group were higher than those in cirrhosis group (P<0.01). There was no significant difference between CHB group and healthy group (P>0.05). In addition, the AST, ALT, TBIL and ALB gradually increased with the development of hepatocellular carcinoma (P<0.05). The levels of Th22 and IL-22 in liver cirrhosis group and hepatocellular carcinoma group were higher than those in healthy subjects (P<0.05). Th22 and IL-22 levels in hepatitis B liver cancer group were higher than those in hepatitis B cirrhosis group (P<0.05). The levels of Th22 and IL-22 were gradually increased with the development of hepatocellular carcinoma (P<0.05). Conclusion: Th22 and IL-22 may be related to the occurrence and development of HCC.

Key words： primary hepatocellular carcinoma Th22 cells interleukin-22 hepatitis B

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHI Zhenjing
	WU Daoyi
	WU Lili
	QIAO Binbin
	ZHENG Bingru
	LI Cheng
	SHI Changsheng
	YU Xixiang

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2019.01.004 OR https://xb.wmu.edu.cn/EN/Y2019/V49/I1/15

[1] ZHAO F, KORANGY F, GRETEN T F. Cellular immune suppressor mechanisms in patients with hepatocellular carci-noma[J]. Dig Dis, 2012, 30(5): 477-482.
[2] SUHAIL M, ABDEL-HAFIZ H, ALI A, et al. Potential mechanisms of hepatitis B virus induced liver injury[J]. World J Gastroenterol, 2014, 20(35): 12462-12472.
[3] MOUGIAKAKOS D, CHOUDHURY A, LLADSER A, et al.
Regulatory T cells in cancer[J]. Adv Cancer Res, 2010, 107: 57-117.
[4] 杜勇, 黄智铭, 林秀清, 等. 肝癌小鼠模型中调节性T细胞对树突状细胞的作用[J]. 温州医科大学学报, 2017, 47(10): 718-722.
[5] WANG K, VELLA A T. Regulatory T cells and cancer: A two-sided story[J]. Immunol Invest, 2016, 45(8): 797-812.
[6] 庄磊, 魏永刚, 宋其同, 等. BCLC B期肝癌术后行索拉非尼治疗的疗效分析[J]. 温州医科大学学报, 2015, 45(12): 929-931.
[7] LI J, WANG Z, MAO K, et al. Clinical significance of serum T helper 1/T helper 2 cytokine shift in patients with non-small cell lung cancer[J]. Oncol Lett, 2014, 8(4): 1682-1686.
[8] TERAMOTO K, OHSHIO Y, FUJITA T, et al. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy[J]. J Cancer Res Clin Oncol, 2013, 139(5): 861-870.
[9] BRAUMüLLER H, WIEDER T, BRENNER E, et al. T-helper-1-cell cytokines drive cancer into senescence[J]. Nature, 2013, 494(7437): 361-365.
[10] DUAN M C, ZHONG X N, LIU G N, et al. The Treg/Th17 paradigm in lung cancer[J]. J Immunol Res, 2014, 2014: 730380.
[11] CHANG S H, MIRABOLFATHINEJAD S G, KATTA H,
et al. T helper 17 cells play a critical pathogenic role in lung cancer[J]. Proc Natl Acad Sci U S A, 2014, 111(15): 5664-5669.
[12] 顾磊, 蒋春晖, 孙隆慈, 等. 1,25(OH)_2D_3体外抑制小鼠Th17细胞分化的作用研究[J]. 肝胆胰外科杂志, 2016, 28(3): 213-216.
[13] JIA L, WU C. The biology and functions of Th22 cells[J]. Adv Exp Med Biol, 2014, 841: 209-230.
[14] WOLK K, WITTE E, WITTE K, et al. Biology of interleukin-22[J]. Semin Immunopathol, 2010, 32(1): 17-31.
[15] CHENG F, GUO Z, XU H, et al. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythemato-sus[J]. Ann Rheum Dis, 2009, 68(4): 604-606.
[16] ZENEWICZ L A, YANCOPOULOS G D, VALENZUELA D M, et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation[J]. Immunity, 2007, 27(4): 647-659.
[17] RADAEVA S, SUN R, PAN H N, et al. Interleukin 22(IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 ac-tivation[J]. Hepatology, 2004, 39(5): 1332-1342.
[18] ZHANG Y, COBLEIGH M A, LIAN J Q, et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus[J]. Gastroenterology, 2011, 141(5): 1897-1906.
[19] OGATA H, KOBAYASHI T, CHINEN T, et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis[J]. Gastroenterology, 2006, 131(1): 179-193.
[20] PARK O, WANG H, WENG H, et al. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression[J]. Hepatology, 2011, 54(1): 252-261.
[21] JIANG R, TAN Z, DENG L, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3[J]. Hepatology, 2011, 54(3): 900-909.
[22] 马诗家, 郭晓云, 陶霖, 等. Th22细胞和IL-22在肝癌外周血的表达及与肿瘤标记物的相关性研究[J]. 中国临床新医学, 2014, 7(4): 277-279.